Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Hisse Senetlerindeki Sıralama #12094
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Hisse Fiyatı
$2.34
Son senkronizasyon: 2026-08-28
Piyasa Değeri
$621.44M
Değişim (1 gün)
-1.06%
Değişim (1 yıl)
55.67%
Ülke
GB
Ticaret Autolus Therapeutics plc (AUTL)

Kategori

Autolus Therapeutics plc (AUTL) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $2.28 - 2026-08-01

Gün sonu en düşük fiyat: $26.43 - 2018-06-01
Autolus Therapeutics plc için hisse fiyatı geçmişi: 2018 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.20 -12.94%
AU
$138.18 473.58%
US
$759.27 7.20%
CH